

## **InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting**

**March 15, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced changes in the composition of the Nomination Committee for the 2021 Annual General Meeting due to changes in the ownership structure of the company.**

Changes in the ownership structure of InDex Pharmaceuticals Holding AB (publ) in connection with the rights issue in February 2021 has led to changes in the composition of the Nomination Committee for the 2021 Annual General Meeting.

Following the changes, the Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of:

- Bengt Julander, appointed by Linc
- Ivo Staijen, appointed by HBM Healthcare Investments
- Sussie Kwart, appointed by Handelsbanken Funds
- Björn Wasing, appointed by SEB-Stiftelsen
- Wenche Rolfsen, Chairman of the Board (convener)

The responsibility of the Nomination Committee is to present to the 2021 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

The Nomination Committee together represents approximately 30 percent of all voting rights in the company as of February 26, 2021.

Shareholders wishing to submit comments or proposals to the Nomination Committee can send them via email to [info@indexpharma.com](mailto:info@indexpharma.com).

### **For more information:**

Peter Zerhouni, CEO

Phone: +46 8 122 038 50

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

### **Publication**

The information was submitted for publication through the agency of the contact person set out above at 10:30 CET on March 15, 2021.

### **InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The Company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market. Redeye AB with email address [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the Company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com).